Related Experiment Video
Updated: May 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase
Jennifer M F Kwok1, Christopher Cheng-Hwa Ma, Sze Ma
1St Theresa's Hospital, Hong Kong.
Abstract:
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), are important lipid-lowering agents. After two decades of laboratory and clinical studies, their pleiotropic effects appear well-established. One of these effects is through the regulation of Rac1 and NADPH oxidases. Relatively few human trials have been carried out with regards to the action of statins on Rac1 and NADPH oxidases, but similar positive effects were also observed in blood vessels and myocardium of participants in the trials. Besides, more specific biomarkers for the antioxidation effects of statins have been developed in the recent two years; both monitoring of the progress of disease and the effects of medical therapy will be possible. Further development of the potency and specificity of statin may enhance their therapeutic potential on cardiovascular disease.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Nitric Oxide Signaling Pathway